Hsbc Holdings PLC Has $2.19 Million Stock Holdings in Harmony Biosciences Holdings, Inc. $HRMY

Posted by George Bondi on Jun 30th, 2026

Hsbc Holdings PLC lifted its holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Free Report) by 59.8% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 58,589 shares of the company’s stock after purchasing an additional 21,919 shares during the quarter. Hsbc Holdings PLC’s holdings in Harmony Biosciences were worth $2,193,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Invesco Ltd. raised its holdings in Harmony Biosciences by 11.8% in the fourth quarter. Invesco Ltd. now owns 450,805 shares of the company’s stock worth $16,869,000 after purchasing an additional 47,517 shares during the period. Mercer Global Advisors Inc. ADV acquired a new position in Harmony Biosciences in the 4th quarter worth $525,000. State of Tennessee Department of Treasury boosted its stake in Harmony Biosciences by 37.0% in the 4th quarter. State of Tennessee Department of Treasury now owns 36,150 shares of the company’s stock worth $1,320,000 after purchasing an additional 9,768 shares during the period. Mackenzie Financial Corp bought a new position in Harmony Biosciences during the 4th quarter worth about $1,529,000. Finally, Empowered Funds LLC increased its holdings in Harmony Biosciences by 56.9% during the 4th quarter. Empowered Funds LLC now owns 85,153 shares of the company’s stock worth $3,186,000 after purchasing an additional 30,882 shares in the last quarter. Institutional investors own 86.23% of the company’s stock.

Harmony Biosciences Stock Down 0.4%

Shares of HRMY stock opened at $35.34 on Tuesday. The firm’s fifty day moving average price is $32.08 and its two-hundred day moving average price is $32.91. The company has a current ratio of 3.58, a quick ratio of 3.56 and a debt-to-equity ratio of 0.15. Harmony Biosciences Holdings, Inc. has a 1 year low of $25.52 and a 1 year high of $40.87. The firm has a market capitalization of $2.05 billion, a P/E ratio of 14.25, a PEG ratio of 0.25 and a beta of 0.96.

Harmony Biosciences (NASDAQ:HRMY – Get Free Report) last released its earnings results on Thursday, May 7th. The company reported $0.55 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.21). Harmony Biosciences had a net margin of 16.20% and a return on equity of 17.19%. The company had revenue of $215.39 million during the quarter, compared to analyst estimates of $220.84 million. During the same period in the prior year, the firm posted $0.78 EPS. Harmony Biosciences’s revenue was up 16.6% compared to the same quarter last year. On average, equities analysts predict that Harmony Biosciences Holdings, Inc. will post 3.2 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on HRMY shares. Truist Financial boosted their price target on Harmony Biosciences from $25.00 to $29.00 and gave the company a “hold” rating in a report on Friday, May 8th. Zacks Research upgraded Harmony Biosciences from a “strong sell” rating to a “hold” rating in a report on Friday, May 1st. Weiss Ratings raised Harmony Biosciences from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, June 23rd. Finally, HC Wainwright restated a “buy” rating on shares of Harmony Biosciences in a research note on Wednesday, June 24th. Four investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Harmony Biosciences presently has a consensus rating of “Hold” and a consensus price target of $40.89.

View Our Latest Research Report on Harmony Biosciences

Harmony Biosciences Company Profile

(Free Report)

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.